Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 306, Issue 8, 2014, Pages

  Baltgalvis, Kristen A ^a   White, Kathy ^a   Li, Wei ^a   Claypool, Mark D ^a   Lang, Wayne ^a   Alcantara, Raniel ^a   Singh, Baljit K ^a   Friera, Annabelle M ^a   McLaughlin, John ^a   Hansen, Derek ^a   McCaughey, Kelly ^a   Nguyen, Henry ^a   Smith, Ira J ^a   Godinez, Guillermo ^a   Shaw, Simon J ^a   Goff, Dane ^a   Singh, Rajinder ^a   Markovtsov, Vadim ^a   Sun, Tian Qiang ^a   Jenkins, Yonchu ^a   Uy, Gerald ^a   Li, Yingwu ^a   Pan, Alison ^a   Gururaja, Tarikere ^a   Lau, David ^a   Park, Gary ^a   Hitoshi, Yasumichi ^a   Payan, Donald G ^a   Kinsella, Todd M ^a   more..

^a RIGEL PHARMACEUTICALS INC   (United States)

Author keywords

5 AMPactivated protein kinase; Exercise; Intermittent claudication; Nitric oxide; Obesity

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BIOAVAILABILITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EXERCISE; GLUCOSE INTOLERANCE; HEART FUNCTION; HEART OUTPUT; INTERMITTENT CLAUDICATION; LEG MUSCLE; LIPID DIET; MALE; MOUSE; MUSCLE; MUSCLE PERFUSION; NONHUMAN; OBESITY; PERIPHERAL VASCULAR DISEASE; PERIPHERAL VASCULAR INSUFFICIENCY; PRIORITY JOURNAL; RUNNING; SKELETAL MUSCLE; TREADMILL EXERCISE; TREADMILL TEST;

5′-AMP-ACTIVATED PROTEIN KINASE; EXERCISE; INTERMITTENT CLAUDICATION; NITRIC OXIDE; OBESITY;

AGING; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOLIPOPROTEINS E; ARGININE; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ENZYME ACTIVATORS; HUMANS; INTERMITTENT CLAUDICATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE FATIGUE; MUSCLE, SKELETAL; NITRIC OXIDE SYNTHASE TYPE III; OBESITY; PERIPHERAL VASCULAR DISEASES; PHOSPHODIESTERASE 3 INHIBITORS; PHYSICAL EXERTION; TETRAZOLES; VASODILATOR AGENTS;

EID: 84900818845     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00839.2013     Document Type: Article

References (76)

1. Andrikopoulos S, Blair AR, Deluca N, Fam BC, Proietto J. Evaluating the glucose tolerance test in mice. Am J Physiol Endocrinol Metab 295: E1323-E1332, 2008.
2. Bauer TA, Regensteiner JG, Brass EP, Hiatt WR. Oxygen uptake kinetics during exercise are slowed in patients with peripheral arterial disease. J Appl Physiol 87: 809-816, 1999.
3. Belin de Chantemele EJ, Mintz JD, Rainey WE, Stepp DW. Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. Hypertension 58: 271-279, 2011.
4. Bhat HK, Hiatt WR, Hoppel CL, Brass EP. Skeletal muscle mitochondrial DNA injury in patients with unilateral peripheral arterial disease. Circulation 99: 807-812, 1999.
5. Bhattacharya I, Mundy AL, Widmer CC, Kretz M, Barton M. Regional heterogeneity of functional changes in conduit arteries after high-fat diet. Obesity 16: 743-748, 2008.
6. Bradley EA, Eringa EC, Stehouwer CD, Korstjens I, van Nieuw Amerongen GP, Musters R, Sipkema P, Clark MG, Rattigan S. Activation of AMP-activated protein kinase by 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside in the muscle microcirculation increases nitric oxide synthesis and microvascular perfusion. Arterioscler Thromb Vasc Biol 30: 1137-1142, 2010.
7. Brass EP, Hiatt WR, Green S. Skeletal muscle metabolic changes in peripheral arterial disease contribute to exercise intolerance: a pointcounterpoint discussion. Vasc Med 9: 293-301, 2004.
8. Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, Witters LA, Power DA, Ortiz de Montellano PR, Kemp BE. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 443: 285-289, 1999.
9. Coutinho T, Rooke TW, Kullo IJ. Arterial dysfunction and functional performance in patients with peripheral artery disease: a review. Vasc Med 16: 203-211, 2011.
10. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation 71: 510-515, 1985.
11. Davidson EP, Coppey LJ, Calcutt NA, Oltman CL, Yorek MA. Diet-induced obesity in Sprague-Dawley rats causes microvascular and neural dysfunction. Diabetes Metab Res Rev 26: 306-318, 2010.
12. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109: III27-32, 2004.
13. Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes 55: 496-505, 2006.
14. Dragneva G, Korpisalo P, Yla-Herttuala S. Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success. Dis Models Mech 6: 312-322, 2013.
15. Faber JE, Zhang H, Lassance-Soares RM, Prabhakar P, Najafi AH, Burnett MS, Epstein SE. Aging causes collateral rarefaction and increased severity of ischemic injury in multiple tissues. Arterioscler Thromb Vasc Biol 31: 1748-1756, 2011.
16. Feinglass J, Brown JL, LoSasso A, Sohn MW, Manheim LM, Shah SJ, Pearce WH. Rates of lower-extremity amputation and arterial reconstruction in the United States, 1979 to 1996. Am J Public Health 89: 1222-1227, 1999.
17. Fillmore N, Jacobs DL, Mills DB, Winder WW, Hancock CR. Chronic AMP-activated protein kinase activation and a high-fat diet have an additive effect on mitochondria in rat skeletal muscle. J Appl Physiol 109: 511-520, 2010.
18. Gardner AW, Forrester L, Smith GV. Altered gait profile in subjects with peripheral arterial disease. Vasc Med 6: 31-34, 2001.
19. Gardner AW, Killewich LA. Lack of functional benefits following infrainguinal bypass in peripheral arterial occlusive disease patients. Vasc Med 6: 9-14, 2001.
20. Gardner AW, Montgomery PS, Parker DE. Optimal exercise program length for patients with claudication. J Vasc Surg 55: 1346-1354, 2012.
21. Goff D, Payan D, Singh R, Shaw S, Carroll D, Hitoshi Y. AMPKActivating Heterocyclic Compounds and Methods for Using the Same, edited by Organization WIP. San Francisco, CA: Rigel Pharmaceuticals, 2012.
22. Hardie DG. AMP-activated protein kinase: a key system mediating metabolic responses to exercise. Med Sci Sports Exerc 36: 28-34, 2004.
23. Hiatt WR, Hirsch AT, Cooke JP, Olin JW, Brater DC, Creager MA. Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy. Vasc Med 9: 18-25, 2004.
24. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286: 1317-1324, 2001.
25. Joras M, Poredos P. The association of acute exercise-induced ischaemia with systemic vasodilator function in patients with peripheral arterial disease. Vasc Med 13: 255-262, 2008.
26. Kiani S, Aasen JG, Holbrook M, Khemka A, Sharmeen F, LeLeiko RM, Tabit CE, Farber A, Eberhardt RT, Gokce N, Vita JA, Hamburg NM. Peripheral artery disease is associated with severe impairment of vascular function. Vasc Med 18: 72-78, 2013.
27. Kihara H, Hirose K, Koganei H, Sasaki N, Yamamoto H, Kimura A, Nishimori T, Shoji M, Yoshimoto R. AT-1015, a novel serotonin (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesion in rats. J Cardiovasc Pharmacol 35: 523-530, 2000.
28. Kihara H, Koganei H, Hirose K, Yamamoto H, Yoshimoto R. Antithrombotic activity of AT-1015, a potent 5-HT2A receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time. Eur J Pharmacol 433: 157-162, 2001.
29. Komiyama T, Kihara H, Hirose K, Yoshimoto R, Shigematsu H. AT-1015, a novel serotonin2A receptor antagonist, improves resaturation of exercised ischemic muscle in hypercholesterolemic rabbits. J Vasc Surg 39: 661-667, 2004.
30. Lee-Young RS, Ayala JE, Fueger PT, Mayes WH, Kang L, Wasserman DH. Obesity impairs skeletal muscle AMPK signaling during exercise: role of AMPK2 in the regulation of exercise capacity in vivo. Int J Obesity 35: 982-989, 2011.
31. Lee-Young RS, Ayala JE, Hunley CF, James FD, Bracy DP, Kang L, Wasserman DH. Endothelial nitric oxide synthase is central to skeletal muscle metabolic regulation and enzymatic signaling during exercise in vivo. Am J Physiol Regul Integr Comp Physiol 298: R1399-R1408, 2010.
32. Lesniewski LA, Zigler MC, Durrant JR, Donato AJ, Seals DR. Sustained activation of AMPK ameliorates age-associated vascular endothelial dysfunction via a nitric oxide-independent mechanism. Mech Ageing Dev 133: 368-371, 2012.
33. Li Y, Hazarika S, Xie D, Pippen AM, Kontos CD, Annex BH. In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia. Diabetes 56: 656-665, 2007.
34. Lindner JR, Womack L, Barrett EJ, Weltman J, Price W, Harthun NL, Kaul S, Patrie JT. Limb stress-rest perfusion imaging with contrast ultrasound for the assessment of peripheral arterial disease severity. JACC Cardiovasc Imaging 1: 343-350, 2008.
35. Lloyd DJ, Helmering J, Kaufman SA, Turk J, Silva M, Vasquez S, Weinstein D, Johnston B, Hale C, Veniant MM. A volumetric method for quantifying atherosclerosis in mice by using microCT: comparison to en face. PLOS ONE 6: e18800, 2011.
36. Loffredo L, Marcoccia A, Pignatelli P, Andreozzi P, Borgia MC, Cangemi R, Chiarotti F, Violi F. Oxidative-stress-mediated arterial dysfunction in patients with peripheral arterial disease. Eur Heart J 28: 608-612, 2007.
37. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol 47: 921-929, 2006.
38. Maxwell AJ, Niebauer J, Lin PS, Tsao PS, Bernstein D, Cooke JP. Hypercholesterolemia impairs exercise capacity in mice. Vasc Med 14: 249-257, 2009.
39. McKeehen JN, Novotny SA, Baltgalvis KA, Call JA, Nuckley DJ, Lowe DA. Adaptations of mouse skeletal muscle to low-intensity vibration training. Med Sci Sports Exerc 45: 1051-1059, 2013.
40. Meijer WT, Grobbee DE, Hunink MG, Hofman A, Hoes AW. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med 160: 2934-2938, 2000.
41. Morrow VA, Foufelle F, Connell JM, Petrie JR, Gould GW, Salt IP. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem 278: 31629-31639, 2003.
42. Musi N, Fujii N, Hirshman MF, Ekberg I, Froberg S, Ljungqvist O, Thorell A, Goodyear LJ. AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise. Diabetes 50: 921-927, 2001.
43. Naderali EK, Brown MJ, Pickavance LC, Wilding JP, Doyle PJ, Williams G. Dietary obesity in the rat induces endothelial dysfunction without causing insulin resistance: a possible role for triacylglycerols. Clin Sci 101: 499-506, 2001.
44. Niebauer J, Maxwell AJ, Lin PS, Tsao PS, Kosek J, Bernstein D, Cooke JP. Impaired aerobic capacity in hypercholesterolemic mice: partial reversal by exercise training. Am J Physiol Heart Circ Physiol 276: H1346-H1354, 1999.
45. Owusu-Ansah E, Song W, Perrimon N. Muscle mitohormesis promotes longevity via systemic repression of insulin signaling. Cell 155: 699-712, 2013.
46. Padilla J, Jenkins NT, Laughlin MH, Fadel PJ. Blood pressure regulation VIII: resistance vessel tone and implications for a pro-atherogenic conduit artery endothelial cell phenotype. Eur J Appl Physiol 114: 531-544, 2014.
47. Paigen B, Ishida BY, Verstuyft J, Winters RB, Albee D. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. Arteriosclerosis 10: 316-323, 1990.
48. Park SY, Shin HK, Lee JH, Kim CD, Lee WS, Rhim BY, Hong KW. Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor γ transcription. J Pharmacol Exp Ther 329: 571-579, 2009.
49. Parmenter BJ, Raymond J, Fiatarone Singh MA. The effect of exercise on haemodynamics in intermittent claudication: a systematic review of randomized controlled trials. Sports Med 40: 433-447, 2010.
50. Payvandi L, Dyer A, McPherson D, Ades P, Stein J, Liu K, Ferrucci L, Criqui MH, Guralnik JM, Lloyd-Jones D, Kibbe MR, Liang ST, Kane B, Pearce WH, Verta M, McCarthy WJ, Schneider JR, Shroff A, McDermott MM. Physical activity during daily life and brachial artery flow-mediated dilation in peripheral arterial disease. Vasc Med 14: 193-201, 2009.
51. Pipinos II, Judge AR, Selsby JT, Zhu Z, Swanson SA, Nella AA, Dodd SL. The myopathy of peripheral arterial occlusive disease: part 1. Functional and histomorphological changes and evidence for mitochondrial dysfunction. Vasc Endovasc Surg 41: 481-489, 2007.
52. Pipinos II, Judge AR, Zhu Z, Selsby JT, Swanson SA, Johanning JM, Baxter BT, Lynch TG, Dodd SL. Mitochondrial defects and oxidative damage in patients with peripheral arterial disease. Free Radic Biol Med 41: 262-269, 2006.
53. Regensteiner JG, Hargarten ME, Rutherford RB, Hiatt WR. Functional benefits of peripheral vascular bypass surgery for patients with intermittent claudication. Angiology 44: 1-10, 1993.
54. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg 23: 104-115, 1996.
55. Regensteiner JG, Wolfel EE, Brass EP, Carry MR, Ringel SP, Hargarten ME, Stamm ER, Hiatt WR. Chronic changes in skeletal muscle histology and function in peripheral arterial disease. Circulation 87: 413-421, 1993.
56. Respress JL, Wehrens XH. Transthoracic echocardiography in mice. J Vis Exp; doi:10.3791/1738.
57. Rogers GW, Brand MD, Petrosyan S, Ashok D, Elorza AA, Ferrick DA, Murphy AN. High throughput microplate respiratory measurements using minimal quantities of isolated mitochondria. PLOS ONE 6: e21746, 2011.
58. Schror K. The pharmacology of cilostazol. Diabetes Obesity Metab 4, Suppl 2: S14-S19, 2002.
59. Smith GD, Shipley MJ, Rose G. Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study. Circulation 82: 1925-1931, 1990.
60. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37: 1163-1167, 1988.
61. Suzuki K, Uchida K, Nakanishi N, Hattori Y. Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes. Am J Hypertens 21: 451-457, 2008.
62. Terai M, Ohishi M, Ito N, Takagi T, Tatara Y, Kaibe M, Komai N, Rakugi H, Ogihara T. Comparison of arterial functional evaluations as a predictor of cardiovascular events in hypertensive patients: the Non-Invasive Atherosclerotic Evaluation in Hypertension (NOAH) study. Hypertens Res 31: 1135-1145, 2008.
63. Tunis SR, Bass EB, Steinberg EP. The use of angioplasty, bypass surgery, and amputation in the management of peripheral vascular disease. N Engl J Med 325: 556-562, 1991.
64. Vasquez SX, Gao F, Su F, Grijalva V, Pope J, Martin B, Stinstra J, Masner M, Shah N, Weinstein DM, Farias-Eisner R, Reddy ST. Optimization of microCT imaging and blood vessel diameter quantitation of preclinical specimen vasculature with radiopaque polymer injection medium. PLOS ONE 6: e19099, 2011.
65. Watson L, Ellis B, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev: CD000990, 2008.
66. West DB, Boozer CN, Moody DL, Atkinson RL. Dietary obesity in nine inbred mouse strains. Am J Physiol Regul Integr Comp Physiol 262: R1025-R1032, 1992.
67. Wiedeman MP. Dimensions of blood vessels from distributing artery to collecting vein. Circ Res 12: 375-378, 1963.
68. Williams G, Shi-Wen X, Abraham D, Selvakumar S, Baker DM, Tsui JC. Nitric oxide manipulation: a therapeutic target for peripheral arterial disease? Cardiol Res Pract 2012: 656247, 2012.
69. Wilson AM, Shin DS, Weatherby C, Harada RK, Ng MK, Nair N, Kielstein J, Cooke JP. Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. Vasc Med 15: 267-274, 2010.
70. Winder WW, Holmes BF, Rubink DS, Jensen EB, Chen M, Holloszy JO. Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol 88: 2219-2226, 2000.
71. Xu Q, Si LY. Protective effects of AMP-activated protein kinase in the cardiovascular system. J Cell Mol Med 14: 2604-2613, 2010.
72. Yataco AR, Corretti MC, Gardner AW, Womack CJ, Katzel LI. Endothelial reactivity and cardiac risk factors in older patients with peripheral arterial disease. Am J Cardiol 83: 754-758, 1999.
73. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258: 468-471, 1992.
74. Zhang Y, Lee TS, Kolb EM, Sun K, Lu X, Sladek FM, Kassab GS, Garland T Jr, Shyy JY. AMP-activated protein kinase is involved in endothelial NO synthase activation in response to shear stress. Arterioscler Thromb Vasc Biol 26: 1281-1287, 2006.
75. Ziegler MA, Distasi MR, Bills RG, Miller SJ, Alloosh M, Murphy MP, Akingba AG, Sturek M, Dalsing MC, Unthank JL. Marvels, mysteries, and misconceptions of vascular compensation to peripheral artery occlusion. Microcirculation 17: 3-20, 2010.
76. Zou MH, Wu Y. AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function. Clin Exp Pharmacol Physiol 35: 535-545, 2008.